secwatch.observer — SEC 8-K summary
======================================

Issuer:     BiomX Inc. (PHGE)
CIK:        0001739174
Form:       8-K
Filed at:   2024-04-15T23:59:59+00:00
Accession:  0001213900-24-033032
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BiomX appoints Susan Blum to board as Class II director and audit committee chair; amends bylaws
--------------------------------------------------------------------------------

- Board size increased to eight; Susan Blum appointed as Class II director with term expiring at 2025 annual meeting.
- Blum named chair of audit committee and designated audit committee financial expert.
- Blum is CFO of Melinta Therapeutics; previously VP Finance & CAO at Melinta, controller at Textura, and director at Orbitz.
- Bylaws amended to eliminate requirement that board and committees be comprised of an odd number of directors.
- Indemnification agreement entered into with Blum; terms consistent with other directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739174/000121390024033032/0001213900-24-033032-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739174/000121390024033032/ea0203936-8k_biomxinc.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-033032

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer